Companies › OSE Immunotherapeutics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OSE2101 peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an | TP53, ERBB2, CEA, MAGEA2, MAGEA3 | Phase 3 | Patients With Non-Small Cell Lung Cancer; Solid Advanced Tumor | Dec 2027 |
| OSE-279 PD-1 blocking monoclonal antibody | PDCD1 | Phase 1 | Solid Advanced Tumor | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06472245 | OSE2101 | Phase 3 | Patients With Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT05751798 | OSE-279 | Phase 1 | Solid Advanced Tumor | Oncology | Dec 2029 |
| NCT05751798 | OSE2101 | Phase 1 | Solid Advanced Tumor | Oncology | Dec 2029 |
Advenchen Laboratories Advenchen Laboratories Nanjing Nuvalent Clarity Pharmaceuticals TYK Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.